2020 Archives - ISA Therapeutics BV

ISA Pharmaceuticals October 2020 Virtual Conference Calendar

07 Oct 2020

ISA will be attending the following virtual conferences in October.

Optimum’s 12th Annual Healthcare Investor Conference8 October 2020Gerben Moolhuizen, Chief Executive Officer will be attending

BIO Investor Forum Digital13 – 15 October 2020Anton Mat, Director Business Development will be attending

Solebury Trout Fall Private Company Showcase 202015 October 2020Gerben Moolhuizen, Chief Executive Officer will be presenting at the 7th Solebury Trout Private Company Showcase co-hosted by BMO and Davis Polk. You are welcome to tune in.

Time: 4:00pm CET / 10:00am EDT.Webcast: https://www.webcaster4.com/Webcast/Page/2408/37724

You may access the stream 15 minutes in advance and a replay of the webcast will be available for 60 days.

Bio Europe

ISA Pharmaceuticals to present at the Virtual 6th Solebury Trout Summer 2020 Private Company Showcase

06 Aug 2020

ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

20 Jul 2020

ISA Pharmaceuticals will move to BioPartner 5

10 Jul 2020

The deal is sealed. This week contracts were signed to make it official: ISA will move to the new BioPartner 5 building as soon as it is ready.

Over the past period we have been expanding and further growth is anticipated. We’re on a roll and rapidly outgrowing our current offices and lab space. Our collaboration with Regeneron for our lead asset ISA101b is booming and we are about to enter the clinic with other therapeutics in our pipeline.

To accommodate future expansion – in line with an aggressive growth strategy – we will move to a new building and double in

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

01 Jul 2020

Leiden, The Netherlands, 01 July 2020 — ISA Pharmaceuticals B.V., today announced that it received Orphan Drug Designation from the Food and Drug Administration (FDA) in the USA for its lead product ISA101b for treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer.

According to the latest statistics of the Centers for Disease Control and Prevention, HPV causes more than 34,000 cases of cancer in the United States each year. Cervical cancer is the most common HPV-associated cancer in women, with HPV16 being responsible for approximately 50% of cases. HPV16-positive cervical cancer is the number 2 cause of cancer for women in

ISA Pharmaceuticals to present at the Virtual European Biotech Investor Day 2020

23 Jun 2020

Access to live broadcast ISA presentation at Virtual European Biotech Investor Day on June 25, 2020

22 Jun 2020

Date: Thursday, June 25, 2020

Time Europe: 3:40pm CET = Time US 9:40am EDT

Webcast: https://www.webcaster4.com/Webcast/Page/2408/35366

About ISA Pharmaceuticals

ISA Pharmaceuticals is an immunotherapy company developing treatments for various cancers and infectious diseases. ISA Pharmaceuticals has best-in-class technology to stimulate and activate the human immune system, specifically T cells, to fight diseased or infected cells. ISA Pharmaceuticals has a collaboration with Regeneron for its lead asset, ISA101b, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer. ISA101b is currently in a Phase 2 clinical trial for first- and second-line HPV16-induced head-and-neck cancer, in combination with Libtayo, a PD-1 antibody.

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

17 Jun 2020

Leiden, The Netherlands, June 17, 2020, — ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, today announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo® (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals.

The new oropharyngeal cancer trial is
the third trial planned under the clinical collaboration between ISA Pharmaceuticals
and Regeneron. ISA101b, an immunotherapy targeting human papillomavirus type 16
(HPV16), is currently in a Phase 2 clinical trial for first- and second-line
HPV16-positive head-and-neck cancer in combination with

Vaccine + chemo activate immune response against cervical cancer

09 Apr 2020

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer

30 Mar 2020

Blog by Arthur N. Brodsky, PhD, published on Cancerresearch.org on 27 March 2020. Click here to access the original article.

Just weeks after International Human Papilloma Virus (HPV) Awareness
Day, new results
from two long-time Cancer Research Institute (CRI) scientists highlighted the
promise of immunotherapy against HPV-associated cervical cancer.

In a phase 1/2 study, women with advanced, recurrent, or
metastatic cervical cancer were treated with the combination of an
HPV-targeting vaccine and standard-of-care chemotherapy. Of 72 evaluable
patients, 43 percent had their tumors shrink.

Led by Cornelis J.
M. Melief, M.D, Ph.D., and Sjoerd H. van der Burg, Ph.D.,
this clinical breakthrough was the latest fruit borne by the duo, both of
whom have been supported